olaratumab
Sign in to saveAlso known as Lartruvo, IMC-3G3, LY-3012207
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
Research
131 papers- Olaratumab.2006
- Olaratumab: First Global Approval.Drugs · 2017
- Olaratumab.2012
- Olaratumab for the treatment of soft-tissue sarcoma.Future oncology (London, England) · 2017
- Olaratumab in the management of advanced soft tissue sarcoma.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2019
via PubMed
Wikidata facts
Show 2 more facts
- World Health Organisation international non-proprietary name
- olaratumab
- chemical formula
- C₆₅₅₄H₁₀₀₇₆N₁₇₃₆O₂₀₄₈S₄₀
Sources (3)
via Wikidata · CC0
~4 min read
Article
9 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- References
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").
Connections
United States Food and Drug Administration
Entity
neoplasm
Entity
pharmacokinetics
Entity
fusion protein
Entity
phase of clinical research
Entity
dinutuximab
Entity
VEGF receptors
Entity
MET proto-oncogene, receptor tyrosine kinase
Protein
European Union
Concept
human
Entity
digital object identifier
Entity
leukemia
Entity
chemical formula
Entity
insulin
Entity
European Commission
Entity
testosterone
Entity
lymphatic system
Entity
adaptive radiation therapy
Entity
molar mass
Entity
nausea
Entity